Arab Journal of Gastroenterology
Volume 10, Issue 4, Supplement , Pages S12-S16 , April 2010

Potential novel biomarkers for monitoring the fibrogenic process in liver

  • Axel M. Gressner

      Affiliations

    • Institute of Clinical Chemistry and Pathobiochemistry – Central Laboratory, RWTH-University Hospital Aachen, Pauwelsstr. 30, 52074 Aachen, Germany
    • Corresponding Author InformationCorresponding author.
    • ,
  • Mohamed Rizk

      Affiliations

    • Institute of Clinical Chemistry and Pathobiochemistry – Central Laboratory, RWTH-University Hospital Aachen, Pauwelsstr. 30, 52074 Aachen, Germany
    • ,
  • Chunfang Gao

      Affiliations

    • Department of Laboratory Medicine, Eastern Hepatobiliary Hospital (EHBH), Second Military Medical University, 225 Shanghai Road, Shanghai 200438, China
    • ,
  • Olav A. Gressner

      Affiliations

    • Institute of Clinical Chemistry and Pathobiochemistry – Central Laboratory, RWTH-University Hospital Aachen, Pauwelsstr. 30, 52074 Aachen, Germany

References 

  1. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med. 2006;10:76–99
  2. Collazos J, Diaz F. Role of the measurement of serum procollagen type III N-terminal peptide in the evaluation of liver diseases. Clin Chim Acta. 1994;227:37–43
  3. Lydatakis H, Hager IP, Kostadelou E, Mpousmpoulas S, Pappas S, Diamantis I. Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. Liver Int. 2006;26:864–871
  4. Kropf J, Gressner AM, Tittor W. Logistic-regression model for assessing portal hypertension by measuring hyaluronic acid (hyaluronan) and laminin in serum. Clin Chem. 1991;37:30–35
  5. Flisiak R, Maxwell P, Prokopowicz D, Timms PM, Panasiuk A. Plasma tissue inhibitor of metalloproteinases-1 and transforming growth factor beta 1 – possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis. Hepato-Gastroenterol. 2002;49:1369–1372
  6. Roth S, Michel K, Gressner AM. (Latent) transforming growth factor-beta in liver parenchymal cells, its injury-dependent release and paracrine effects on hepatic stellate cells. Hepatology. 1998;27:1003–1012
  7. Gressner AM, Yagmur E, Lahme B, Gressner O, Stanzel S. Connective tissue growth factor in serum as a new candidate test for assessment of hepatic fibrosis. Clin Chem. 2006;52:1815–1817
  8. Gressner O, Lahme B, Demirci I, Gressner AM, Weiskirchen R. Differential effects of TGF-beta on connective tissue growth factor (CTGF/CCN2) expression in hepatic stellate cells and hepatocytes. J Hepatol. 2007;47:699–710
  9. Saitou Y, Shiraki K, Yamanaka Y, Yamaguchi Y, Kawakita T, Yamamoto N, et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol. 2005;11:476–481
  10. Tran A, Benzaken S, Saint-Paul MC, Guzman-Granier E, Hastier P, Pradier C, et al. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur J Gastroenterol Hepatol. 2000;12:989–993
  11. Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers R, Thabut D, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol. 2004;3:8
  12. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–526
  13. Rosenberg WMC, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127:1704–1713
  14. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005;51:1867–1873
  15. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol. 2005;4:10
  16. Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol. 2006;44:462–474
  17. Sebastiani G, Vario A, Guido M, Noventa F, Plebani M, Pistis R, et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol. 2006;44:686–693
  18. Rosenthal-Allieri MA, Peritore ML, Tran A, Halfon P, Benzaken S, Bernard A. Analytical variability of the Fibrotest proteins. Clin Biochem. 2005;38:473–478
  19. Quan TE, Cowper S, Wu SP, Bockenstedt LK, Bucala R. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol. 2004;36:598–606
  20. Kubota A, Okamura S, Omori F, Shimoda K, Otsuka T, Ishibashi H, et al. High serum levels of granulocyte-macrophage colony-stimulating factor in patients with liver cirrhosis and granulocytopenia. Clin Lab Haematol. 1995;17:61–63
  21. Gressner OA, Rizk MS, Kovalenko E, Weiskirchen R, Gressner AM. Changing the pathogenetic roadmap of liver fibrosis? Where did it start – where will it go. J Gastroenterol Hepatol. 2008;23:1024–1035
  22. Tacke F, Gäbele E, Bataille F, Schwabe RF, Hellerbrand C, Klebl F, et al. Bone morphogenetic protein 7 is elevated in patients with chronic liver disease and exerts fibrogenic effects on human hepatic stellate cells. Dig Dis Sci. 2007;52:3404–3415
  23. Kuhn J, Prante C, Schon S, Gotting C, Kleesiek K. Measurement of fibrosis marker xylosyltransferase I activity by HPLC electrospray ionization tandem mass spectrometry. Clin Chem. 2006;52:2243–2249
  24. Gressner AM. Activation of proteoglycan synthesis in injured liver – a brief review of molecular and cellular aspects. Eur J Clin Chem Clin Biochem. 1994;32:225–237
  25. Poon TCW, Hui AY, Chan HLY, Ang IL, Chow SM, Wong N. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem. 2005;51:328–335
  26. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med. 2004;10:429–434
  27. Mardini H, Record C. Detection assessment and monitoring of hepatic fibrosis: biochemistry or biopsy?. Ann Clin Biochem. 2005;42:441–447

PII: S1687-1979(09)00316-5

doi: 10.1016/j.ajg.2009.12.009

Arab Journal of Gastroenterology
Volume 10, Issue 4, Supplement , Pages S12-S16 , April 2010

Article Tools